6:54 PM
 | 
Dec 11, 2012
 |  BC Extra  |  Clinical News

Durata's dalbavancin meets endpoint in Phase III ABSSSI trial

Durata Therapeutics Inc. (NASDAQ:DRTX) said IV dalbavancin met the FDA-defined primary endpoint of non-inferiority to twice-daily vancomycin in the 573-patient Phase III DISCOVER 1 trial to treat acute bacterial skin and skin structure infections (ABSSSI). Specifically, dalbavancin was non-inferior to vancomycin in the proportion of patients in the...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >